UK pharmaceutical giant AstraZeneca has entered into an exclusive license agreement with China's CSPC Pharmaceutical Group (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia, according to a media release.
¬ Haymarket Media Limited. All rights reserved.
